Product Description
Mechanisms of Action: COX Inhibitor,PG Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical,Transdermal
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Canada | Chile | Colombia | Denmark | Egypt | Finland | France | Germany | Iceland | Ireland | Italy | Netherlands | New Zealand | Norway | Portugal | South Africa | Sweden | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|